Novartis plans to submit a supplementary new drug application with the FDA for Cosentyx in axial spondyloarthritis.
Cosentyx led to a decrease in disease activity for patients compared to patients who received a placebo in a Phase III trial. It also showed a sustained response and had a consistent safety profile at 52 weeks.
According to Novartis, there are roughly 1.7 million patients in the U.S. and European Union with axial spondyloarthritis.
More articles on devices:
How CTL Amedica has grown since the $10M acquisition in spine, and what lies ahead
Zimmer Biomet recalls legacy products & more: 10 device company notes
Sectra adds DePuy Synthes templates to preoperative planning solution — 3 details
